<?xml version="1.0" encoding="UTF-8"?>
<p>In moving forward, the EAC MRH initiative may also want to consider how it will handle the postapproval regulatory burden (i.e., managing consistency across labeling changes) for jointly approved products, as the work required to regulate variations for new drugs is considerable. In addition, implementing reliance models would help the initiative maximize its public health returns, though the program will need industryâ€™s cooperation to identify information that has been updated since previous application reviews by trusted regulatory authorities, as well as EAC-specific aspects of applications.</p>
